These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 32984952)

  • 1. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
    Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer.
    Nakamura Y; Yokoyama S; Matsuda K; Tamura K; Mitani Y; Iwamoto H; Mizumoto Y; Murakami D; Kitahata Y; Yamaue H
    Sci Rep; 2021 Jan; 11(1):441. PubMed ID: 33432066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    Parikh AR; Chee BH; Tsai J; Rich TA; Price KS; Patel SA; Zhang L; Ibrahim F; Esquivel M; Van Seventer EE; Jarnagin JX; Raymond VM; Corvera CU; Hirose K; Nakakura EK; Corcoran RB; Van Loon K; Atreya CE
    Clin Cancer Res; 2024 Jul; 30(14):2964-2973. PubMed ID: 38695832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 9. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
    Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer.
    Max Ma X; Bendell JC; Hurwitz HI; Ju C; Lee JJ; Lovejoy A; Mancao C; Nicholas A; Price R; Sommer N; Tikoo N; Yao L; Yaung SJ; Palma JF
    Clin Cancer Res; 2020 Aug; 26(15):4010-4017. PubMed ID: 32220893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
    Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
    Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
    Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.
    Tie J; Cohen JD; Wang Y; Li L; Christie M; Simons K; Elsaleh H; Kosmider S; Wong R; Yip D; Lee M; Tran B; Rangiah D; Burge M; Goldstein D; Singh M; Skinner I; Faragher I; Croxford M; Bampton C; Haydon A; Jones IT; S Karapetis C; Price T; Schaefer MJ; Ptak J; Dobbyn L; Silliman N; Kinde I; Tomasetti C; Papadopoulos N; Kinzler K; Volgestein B; Gibbs P
    Gut; 2019 Apr; 68(4):663-671. PubMed ID: 29420226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
    Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
    Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients.
    Yamauchi M; Urabe Y; Ono A; Miki D; Ochi H; Chayama K
    Int J Cancer; 2018 Apr; 142(7):1418-1426. PubMed ID: 29134647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer.
    Gao Z; Huang D; Chen H; Yang Y; An K; Ding C; Yuan Z; Zhai Z; Niu P; Gao Q; Cai J; Zeng Q; Wang Y; Hong Y; Rong W; Huang W; Lei F; Wang X; Chen S; Zhao X; Bai Y; Gu J
    J Transl Med; 2023 Jan; 21(1):63. PubMed ID: 36717891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
    Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
    Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
    Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
    Maron SB; Chase LM; Lomnicki S; Kochanny S; Moore KL; Joshi SS; Landron S; Johnson J; Kiedrowski LA; Nagy RJ; Lanman RB; Kim ST; Lee J; Catenacci DVT
    Clin Cancer Res; 2019 Dec; 25(23):7098-7112. PubMed ID: 31427281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.